Drug intelligence / Profile preview

measles virus vaccine live

Development stage
Phase 4
Lead developer
Merck
Modality
Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intramuscular, Inhalation
01

Overview

The measles vaccine is a live attenuated viral vaccine primarily used for the active immunization of children and adults against measles infection. Most modern formulations are derived from the Edmonston strain, including the Moraten, Schwarz, and Edmonston-Zagreb lineages. The vaccine works by inducing a robust Th1-mediated immune response and the production of neutralizing antibodies that target the measles virus hemagglutinin (H) and fusion (F) proteins, thereby preventing viral entry into host cells via receptors such as CD46, CD150 (SLAM), and Nectin-4. Beyond its primary role in public health, the vaccine has been investigated for its oncolytic potential in treating solid tumors, such as ovarian cancer, and for its immunomodulatory effects in inflammatory conditions like atopic dermatitis. It is frequently administered as a monovalent injection or as part of combination vaccines such as MMR (measles, mumps, and rubella) or MMRV (measles, mumps, rubella, and varicella).

Brand names
AttenuvaxRouvaxLirugen
Other names
measles vaccinelive attenuated measles vaccineMoraten measles vaccineEdmonston-Zagreb measles vaccineSchwarz measles vaccinemeasles-containing vaccineMCV

Beyond the preview

Go deeper on measles virus vaccine live.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on measles virus vaccine live.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call